Alex Azar II, Son of Ophthalmologist, is New Secretary of Health and Human Services

February 2, 2018: By Joan McKenna

Alex Azar II

Alex Azar II, the son of ophthalmologist Alex Azar, MD, is the new secretary of the US Department of Health and Human Services.

The Senate confirmed Azar’s nomination Jan. 24.

The senior Azar has practiced ophthalmology in Salisbury, Maryland, since 1976 and teaches at Johns Hopkins. He told a local paper that his son’s appointment is the epitome of the American dream, given that his father immigrated to the US from Lebanon 100 years ago.

The new secretary, 50, worked at Lilly USA from 2007 to January 2017, ascending to the role of president. He served as general counsel and deputy secretary in Health and Human Services in the George W. Bush administration.

He earned a law degree from Yale, then clerked for Judge Antonin Scalia in an appeals court. He also worked under special prosecutor Ken Starr in the early years of the Whitewater investigation.

Sen. Rand Paul, MD, an ophthalmologist from Kentucky, was the only GOP member to vote against Azar’s nomination. Paul said he couldn’t back confirmation unless Azar showed he was open to the idea of allowing drugs to be imported from other countries where they often cost much less.


Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023